Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:88-95

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Whittaker, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Whittaker, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Acute coronary syndromes
Right arrow Acute myocardial infarction
Right arrow Platelets
Right arrow Receptor pharmacology
Right arrow Animal models of human disease
Right arrow Ischemic biology - basic studies

(Circulation. 2000;102:88.)
© 2000 American Heart Association, Inc.


Basic Science Reports

Brief Antecedent Ischemia Enhances Recombinant Tissue Plasminogen Activator–Induced Coronary Thrombolysis by Adenosine-Mediated Mechanism

Karin Przyklenk, PhD; Peter Whittaker, PhD

From the Heart Institute, Good Samaritan Hospital, and the Department of Medicine, University of Southern California, Los Angeles.

Correspondence to Karin Przyklenk, PhD, Heart Institute/Research, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017-2395. E-mail karinp{at}dnamail.com

Background—Clinical studies have implicated preinfarct angina (brief antecedent ischemia/reperfusion [I/R]) as a predictor of more rapid thrombolysis and lower rates of reocclusion. However, the effects of antecedent ischemia on the efficacy of thrombolysis have not been rigorously assessed. Using a canine model of coronary thrombosis, we aimed to (1) reproduce these clinical findings and (2) determine whether release of adenosine (a potent inhibitor of platelet aggregation via stimulation of platelet A2 receptors) during brief I/R contributes to this improved patency.

Methods and Results—To address our first objective, we compared the time required to achieve lysis with recombinant tissue plasminogen activator and patency during the first 2 hours after lysis in dogs in which 1-hour thrombotic occlusion was preceded by brief I/R (10-minute coronary occlusion/10-minute reperfusion) versus 20-minute uninterrupted perfusion (controls). Time to lysis was accelerated in the I/R group versus the control group (11±1 versus 35±6 minutes, P=0.004). In addition, the duration of subsequent reocclusion was reduced (17±12 versus 30±11 minutes), and the area of the flow-time profile (normalized to baseline flowx120 minutes) was increased (64±12% versus 35±7%, P=0.04) in the I/R cohort. The protocol was then repeated, but all dogs were pretreated with the adenosine A2/A1 antagonist CGS 15943 (CGS, 1.5 mg/kg). Time to lysis (38 versus 39 minutes) and subsequent patency were comparable in the CGS+control group versus the CGS+I/R group.

Conclusions—Brief antecedent I/R enhances the efficacy of coronary thrombolysis in this canine model, which is due, at least in part, to an adenosine-mediated mechanism.


Key Words: ischemia • thrombolysis • adenosine • myocardial infarction




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
E. A. Amsterdam and S. Schaefer
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?
J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1515 - 1516.
[Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. M. YELLON and J. M. DOWNEY
Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology
Physiol Rev, October 1, 2003; 83(4): 1113 - 1151.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. A Kloner, M. T Speakman, and K. Przyklenk
Ischemic preconditioning: a plea for rationally targeted clinical trials
Cardiovasc Res, August 15, 2002; 55(3): 526 - 533.
[Full Text] [PDF]